News | Remote Monitoring | February 17, 2016

Remote Telemonitoring Does Not Reduce Heart Failure Readmissions

While readmissions, mortality do not decrease, researchers see improvements in 180-day quality of life compared to standard care

February 17, 2016 — Increasingly patients and providers are interested in using remote monitoring devices to help with their healthcare. Researchers at the University of California Los Angeles (UCLA) sought to determine if these devices could be useful in preventing 180-day all-cause hospital readmissions for heart failure patients.

They enrolled 1,437 patients from UCLA, UC Davis, UC Irvine, UC San Diego, UC San Francisco and Cedars-Sinai Medical Center in Los Angeles who were randomized into two groups. One group received pre-discharge self-management health coaching along with a Bluetooth-enabled scale, Bluetooth blood pressure/text message device and a transmission pod, and were asked to do daily measurements and answer symptom questions. These measures were checked daily by a centralized nurse call center and if measurements were too high or too low, patients were called to determine what the problem was and if necessary were referred to their healthcare providers or an emergency department. Patients also received scheduled reinforcement of health coaching on a weekly basis for the first month and then monthly through six months. The control group received standard care. The enrollment procedures had very few exclusion criteria in order to mirror potential actual use by health systems, so that patients with a wide range of socioeconomic backgrounds and health comorbidities were enrolled in the study.

The researchers found that combined health coaching and remote monitoring did not reduce all-cause 180-day hospital readmissions among heart failure patients, and did not have significant effects on 30-day hospital readmissions, 30-day mortality or 180-day mortality. These findings were previously reported at the American Heart Association (AHA) scientific meeting on Nov. 8, 2015.

This study additionally reported on quality of life findings not presented at the AHA meeting. The researchers found that intervention patients reported significantly improved quality of life at 180 days when compared to usual care patients based on the Minnesota Living with Heart Failure questionnaire, a well-validated instrument for measuring quality of life among heart failure patients.

The authors concluded that the use of remote monitoring technology is not yet ready for widespread adoption for the purposes of reducing readmissions. A major issue requiring further research is who can adhere to using these technologies and how to improve adherence. Also, further research is needed to evaluate quality of life benefits.

Michael Ong, M.D., Ph.D., associate professor-in-residence of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA, is the study’s lead investigator.

Results were published in the Feb. 8 issue of JAMA Internal Medicine.

For more information: www.archinte.jamanetwork.com/journal


Related Content

News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
Subscribe Now